筑波大学

博士(医学)学位論文

Clinical Significance of a Spiral Phenomenon in the Plot of CO₂ Output versus O₂ Uptake During Exercise in Cardiac Patients (心疾患患者の運動時の二酸化炭素排出量と酸素摂取量のプ ロットにおける「うずまき現象」の臨床的意義)

2015

筑波大学大学院博士課程人間総合科学研究科

長山 医

Clinical Significance of a Spiral Phenomenon in the Plot of CO₂ Output versus O₂ Uptake During Exercise in Cardiac Patients

Running head: Spiral phenomenon in VCO2-versus-VO2 plot

Osamu Nagayama, BS^{a)b)}, Akira Koike, MD^{c)d)}, Tomoko Himi, MD^{b)e)}, Koji Sakurada, MS^{a)}, Yuko Kato, MD^{a)}, Shinya Suzuki, MD^{a)}, Akira Sato, MD^{d)}, Takeshi Yamashita, MD^{a)}, Karlman Wasserman, MD, PhD^{f)}, and Kazutaka Aonuma, MD^{d)}.

- a) The Cardiovascular Institute, Tokyo, Japan
- b) Institute of Clinical Medicine, Graduate School of Comprehensive Human Science, University of Tsukuba, Tsukuba, Japan
- c) Medical Science, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
- d) Cardiology Division, Institute of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
- e) Kawaguchi Kogyo General Hospital, Kawaguchi, Japan
- f) Harbor-UCLA Medical Center, Torrance, CA, USA

Address for correspondence and reprints:

Akira Koike, MD

Faculty of Medicine, University of Tsukuba,

1-1-1, Tennodai, Tsukuba, Ibaraki 305-8575

Japan

Telephone: +81-29-853-3435, Fax: +81-29-853-3435 E-mail: koike@md.tsukuba.ac.jp

ABSTRACT

A spiral phenomenon is sometimes noted in the plots of CO_2 output (VCO₂) against O_2 uptake (VO₂) measured during cardiopulmonary exercise testing (CPX) in heart failure patients with oscillatory breathing. However, few data are available that elucidate the clinical significance of this phenomenon. Our group studied the prevalence of this phenomenon and its relation to cardiac and cardiopulmonary function. Among 2,263 cardiac patients who underwent CPX, 126 patients with a clear pattern of oscillatory breathing were identified. Cardiopulmonary indices were compared between patients who showed the spiral phenomenon (n=49) and those who did not (n=77). The amplitudes of VO_2 and VCO_2 oscillations were higher and the phase difference between VO₂ and VCO₂ oscillations was longer in the patients with the spiral phenomenon than in those without it. Patients with the spiral phenomenon also had a lower left ventricular ejection fraction (43.4±21.4 vs. 57.1 \pm 16.8 %, p<0.001) and a higher level of brain natriuretic peptide (637.2 \pm 698.3 vs. 228.3±351.4 pg/mL, p=0.002). The peak VO₂ was lower (14.5±5.6 vs. 18.1±6.3, p=0.002), the VE-VCO₂ slope was higher (39.8 ± 9.5 vs. 33.6 ± 6.8 , p<0.001), and PETCO₂ both at rest and at peak exercise was lower in the patients with the spiral phenomenon than in those without it. In conclusion, the spiral phenomenon in the VCO₂-versus-VO₂ plot arising from the phase difference between VCO₂ and VO₂ oscillations reflects more advanced cardiopulmonary dysfunction in cardiac patients with oscillatory breathing.

KEY WORDS: cardiopulmonary function, oscillatory breathing, exercise testing

Oscillatory breathing in cardiac patients, a characteristic breathing pattern alternating between hyperpnea and hypopnea, can be evaluated in detail by cardiopulmonary exercise testing (CPX) [1]. Several valuable indices are obtained from CPX, including the peak O₂ uptake (VO₂), the slope of the increase in ventilation (VE) versus the increase in CO₂ output (VCO₂) (VE-VCO₂ slope), and the anaerobic threshold (AT). During incremental exercise below the AT, VCO₂ increases approximately linearly with VO₂, and its slope is theoretically 1.0 or slightly less [2]. The slope above the AT becomes greater than 1.0, because lactic acid is buffered by bicarbonate, resulting in the formation of carbonic acid, which dissociates to water and CO₂ [2]. A peculiar spiral (vortex) phenomenon progressing in a counterclockwise direction is sometimes recognized in the plot of VCO₂ against VO₂ during CPX in heart failure patients with oscillatory breathing [3]. In the present study we determined how frequently the spiral phenomenon can be observed during CPX in cardiac patients with oscillatory breathing and evaluated whether this phenomenon is related to impaired cardiopulmonary function.

METHODS

The subjects for this study were 2,263 consecutive cardiac patients who underwent CPX at the Cardiovascular Institute for the evaluation of exercise capacity and/or severity of heart failure between January 2010 and December 2013. By visual observation, we identified all of subjects who manifested at least three consecutive cycles of clear ventilatory oscillations during the period from the beginning of warm-up exercise until the end of incremental exercise. After determining the amplitude (difference between the peak and nadir) of each VE oscillation, we calculated the percentage amplitude by dividing the amplitude by the mean VE during each oscillation and then calculated the mean value of all oscillations. Thereafter, we selected 126 subjects whose amplitudes were greater than 25 % of the mean VE, based on the report from Murphy et al. [4]. The research protocol was approved by the human subjects committee of the Cardiovascular Institute. The patients were apprised of the purposes and risks of the study, and all of them gave their informed consent.

A symptom-limited incremental exercise test was performed using an upright, electromagnetically braked cycle ergometer (Strength Ergo 8; Mitsubishi Electric Engineering Co., Ltd., Tokyo, Japan). The exercise test began with a 4-min rest on the ergometer followed by a 4-min warm-up at 0 W or 20 W at 60 rpm. The load was then increased incrementally by 1 W every 6 seconds (10 W/min). VO₂, VCO₂, and VE were measured throughout the test using an Aeromonitor AE-300s (Minato Medical Science, Osaka, Japan), as previously described [5]. Before the parameters from the respiratory gas analysis were calculated, breath-by-breath data were interpolated to give second-by-second values. These second-by-second values were then calculated as successive 3-second averages, and the averages were translated into a five-point moving average.

The peak VO₂ was calculated as the average values obtained during the last 15 seconds of incremental exercise. The percentage of peak VO₂ was calculated by dividing the measured peak VO₂ by the predicted peak VO₂. The predicted peak VO₂ was determined based on a normal Japanese population [6]. The gas exchange ratio, which is equal to

 VCO_2/VO_2 , was calculated during the last 15 seconds of incremental exercise. The VE-VCO₂ slope during incremental exercise was calculated by a method previously reported [7]. The end-tidal PCO₂ (PETCO₂) at rest was calculated as the average values obtained during the 4 minutes of rest. The PETCO₂ at peak exercise was calculated as the average of values obtained during the last 15 seconds of incremental exercise.

The amplitude of the oscillating VE was calculated as the difference between the peak and nadir of the oscillating VE for each of the cycles noted from the beginning of warm-up exercise until the end of incremental exercise, and expressed as a mean value. The percentage amplitude was calculated by dividing the amplitude by the mean VE during each oscillation, and expressed as a mean value of all oscillations. The cycle length of the oscillating VE was calculated as the interval from the peak to the following peak of the oscillating VE for each of the cycles, and expressed as a mean value. The amplitude and cycle length of the oscillating VO₂ and VCO₂ were calculated by a similar approach. The oscillatory pattern of VO₂ usually precedes VCO₂ (Figure 1). Thus, the time difference between the peak of the oscillating VO_2 and the corresponding peak of the oscillating VCO_2 (time from the peak of the oscillating VCO_2 ó time of the corresponding peak of the oscillating VO₂) was calculated for each of the cycles and expressed as a mean value. A spiral phenomenon, defined as at least three consecutive counterclockwise changes in the VCO₂-versus-VO₂ plot (i.e., a movement from a left lower side to a right upper side, then slightly to a left upper side, and back to the left lower side, forming an ellipse), was visually identified (Figure 1, panel B for an example of the spiral pattern in a representative subject).

The cardiopulmonary indices were compared between patients who manifested the spiral phenomenon and those who did not.

Data are presented as the mean ± SD. Intergroup differences for variables were compared by the unpaired t-test, or by the Fisher¢ exact test where appropriate. Linear regression analysis was used to correlate the measured variables. All analyses were performed using SPSS version 19.0 software (SPSS Inc., Chicago, Illinois) for Windows (Microsoft Corporation, Redmond, Washington). A p value of less than 0.05 was considered statistically significant for all comparisons.

<u>RESULTS</u>

The peculiar spiral phenomenon was noted in the plots of VCO₂ against VO₂ during CPX in 39% of the cardiac patients with oscillatory breathing. There were no significant differences in gender, age, height, weight, body mass index, or cardiac disease etiology between the patients with and without the spiral phenomenon, though idiopathic dilated cardiomyopathy was more frequent among the former (Table 1).

Similar to the oscillating VE, clear oscillatory changes were noted in both the VO_2 and VCO_2 in the study population overall. The amplitudes and cycle lengths of the VE, VO_2 , and VCO_2 oscillations were all higher in the patients with the spiral phenomenon than in those without it (Table 2). The VO_2 oscillations were found to precede the VCO_2 oscillations in 95 of the 126 subjects. The VCO_2 oscillations preceded the VO_2 oscillations in only one subject, and only by a slight degree. No phase difference between the VO_2 and VCO_2 oscillations was observed in the remaining 30 patients. The mean phase difference between the VO₂ and VCO₂ oscillations was 2.2 ± 2.7 sec in both groups combined, and was significantly larger in the patients with the spiral phenomenon than in those without it (4.4 ± 3.0 sec vs. 0.7 ± 0.8 sec, p<0.001). The phase difference between the VCO₂ and VE oscillations was 0.8 ± 1.0 sec in both groups combined and did not differ between the two groups.

The left ventricular ejection fraction (LVEF) measured by echocardiography was significantly lower in the patients with the spiral phenomenon than in the patients without the spiral phenomenon (Table 2). The level of brain natriuretic peptide (BNP), a parameter measured in 87 out of the 126 patients, was significantly higher in the patients with the spiral phenomenon than in those without it. Meanwhile, the patients with the spiral phenomenon had a significantly lower peak VO₂. The VE-VCO₂ slope was significantly higher in the patients and at peak exercise was significantly lower in the patients with the spiral phenomenon than in those without it.

Figure 2 shows the relation between cardiopulmonary indices and the cycle length of the VO₂ oscillations. The cycle length of the VO₂ oscillations showed significant positive correlations with the BNP and VE-VCO₂ slope, and significant negative correlations with the LVEF and peak VO₂. Figure 3 shows the relation between cardiopulmonary indices and phase difference between the VO₂ and VCO₂ oscillations. The phase difference showed significant positive correlations with the BNP and VE-VCO₂ slope, and significant negative correlations with the LVEF and peak VO₂.

DISCUSSION

In the present study we investigated the clinical significance of the spiral phenomenon in the VCO₂-versus-VO₂ plot recorded during CPX in patients with oscillatory breathing. According to our experiments, 39% of the cardiac patients with oscillatory breathing manifested the spiral phenomenon during exercise. The amplitudes of VO₂ and VCO₂ oscillations were higher and the phase difference between VO₂ and VCO₂ oscillations was longer and in the patients with the spiral phenomenon than in those without it. The patients with the spiral phenomenon exhibited a lower LVEF, higher BNP, lower peak VO₂, higher VE-VCO₂ slope, and lower PETCO₂ than the patients without the spiral phenomenon. The patients with the spiral phenomenon also exhibited the lower heart rate and lower systolic blood pressure at peak exercise, suggesting lower cardiac output during exercise in these patients. Judging from these findings, we concluded that the spiral phenomenon was related to cardiopulmonary dysfunction and could be directly attributed both to the phase difference between the VO₂ and VCO₂ oscillations.

The VE-VCO₂ slope relates mainly to a ventilation/perfusion (V/Q) mismatch, and progressively steepens in patients with heart failure of worsening severity resulting from either systolic or diastolic dysfunction [8,9]. In patients with left ventricular dysfunction, as the hypo-perfusion to the lung caused by reduced pulmonary blood flow exacerbates the V/Q mismatch (high V/Q), leading to progressively lower PETCO₂ as the cardiac disease worsens [1,10,11]. The lower peak VO₂, higher VE-VCO₂ slope, and lower PETCO₂ observed in patients with the spiral phenomenon suggest that the cardiopulmonary dysfunction is more advanced in these patients than in the patients without the spiral phenomenon.

Instability of the respiratory control system is believed to be a major cause of not only central sleep apnea, but also oscillatory breathing during exercise. In 1994, Yajima et al. [12] reported that cardiac patients with oscillatory breathing present oscillatory changes in LVEF with a similar cyclical nature. Since then, fluctuation of the pulmonary blood flow has been proposed as another possible mechanism underlying oscillatory breathing [5,12,13]. VO₂ oscillation, a phenomenon reflective of a change of pulmonary blood flow, preceded the VCO₂ and VE oscillations in most of the subjects in our study. If the VE changes primarily due to a stimulus from the central nervous system to the respiratory muscles, the change of VE must precede the change of VO₂. Our findings may therefore further support the central hypothesis, namely, that fluctuations in the pulmonary blood flow produce oscillatory breathing.

The spiral phenomenon in the VCO₂-versus-VO₂ plot probably derives from both the high amplitudes of the VO₂ and VCO₂ oscillations and the longer phase difference between the oscillations. The VCO₂ kinetics is reported to be slower than the VO₂ kinetics during the onset of exercise [14,15], although the mechanisms responsible for the phase difference between the VO₂ and VCO₂ kinetics are complicated and still undetermined. During mild to moderate exercise, ventilation normally increases at the rate required to remove the additional CO₂ generated in order to keep the arterial PCO₂ and pH close to their resting values [2,15].

Thus, the VE kinetics is usually closely related to the VCO₂ kinetics during exercise [15]. And this, in turn, suggests that the phase difference between the VO₂ and VCO₂ oscillations probably stems not only from the prolonged physiological delay of the VCO₂ kinetics, but also from the delay of the ventilatory response to the fluctuations of the pulmonary CO₂ flow. The latter, in particular, may relate to prolonged circulation time which is known to increase with the severity of heart failure.

There are several limitations in this study. The BNP was obtained only in 87 out of 126 patients in the present study. Our criterion for enrolling subjects with oscillatory breathing was at least three consecutive cycles with an amplitude of greater than 25%. The frequency of the spiral phenomenon in cardiac patients depends on the specific definition used for determining the oscillatory breathing, as well as the severity and/or etiology of cardiac disease in the study population. While -blockers, diuretics, and digitalis were prescribed more frequently in the patients with spiral phenomenon, we could not clearly determine whether one or more of these medications diminished or enhanced the spiral phenomenon. We could not perform a subgroup analysis stratified by heart failure in patients with preserved versus reduced LVEF. We also do not know the relation between the spiral phenomenon and diastolic LV function. A larger study population would be necessary to clarify these issues. Among 2,263 patients who were screened for oscillatory breathing, the exercise tests of 102 patients (4.5%) were prematurely stopped due to adverse signs or symptoms, potentially precluding them from attaining maximum effort.

To our knowledge, this is the first report linking the mechanisms and clinical

significance of the spiral phenomenon in the VCO₂-versus-VO₂ plot in cardiac patients. Our findings indicate that the spiral phenomenon is a novel marker of cardiopulmonary dysfunction during exercise. We believe that the spiral phenomenon can be used to stratify patients with heart failure, although long term follow-up and additional prognostic studies are needed to establish the clinical role of this phenomenon.

- Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, Forman D, Franklin B, Guazzi M, Gulati M, Keteyian SJ, Lavie CJ, Macko R, Mancini D, Milani RV. Clinicianøs guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. *Circulation* 2010; 122: 191-225.
- Wasserman K, Hansen JE, Sue DY, Stringer WW, Sietsema KE, Sun XG, Whipp BJ.
 Principles of Exercise Testing and Interpretation. Philadelphia: Lippincott Williams & Wilkins, 2012.
- Himi T, Koike A, Nagayama O, Sakurada K, Kato J, Yamashita T. A spiral phenomenon in the plot of CO₂ output vs. O₂ uptake in cardiac patients with oscillatory breathing. *Circ* J 2013; 77 (Suppl. I): I-1138 [abstract].
- Murphy RM, Shah RV, Malhotra R, Pappagianopoulos PP, Hough SS, Systrom DM, Semigran MJ, Lewis GD. Exercise oscillatory ventilation in systolic heart failure: an indicator of impaired hemodynamic response to exercise. *Circulation* 2011; 124:1442-1451.
- Kato J, Koike A, Hoshimoto-Iwamoto M, Nagayama O, Sakurada K, Sato A, Yamashita T, Wasserman K, Aonuma K. Relation between oscillatory breathing and cardiopulmonary function during exercise in cardiac patients. *Circ J* 2013; 77:661-666.
- Itoh H, Koike A, Taniguchi K, Marumo F. Severity and pathophysiology of heart failure on the basis of anaerobic threshold (AT) and related parameters. *Jpn Circ J* 1989; 53:146-154.
- 7. Koike A, Itoh H, Kato M, Sawada H, Aizawa T, Fu LT, Watanabe H. Prognostic power of

ventilatory responses during submaximal exercise in patients with chronic heart disease. *Chest* 2002;121:1581-1588.

- Metra M, Dei Cas L, Panina G, Visioli O. Exercise hyperventilation in chronic congestive heart failure, and its relation to functional capacity and hemodynamics. *Am J Cardiol* 1992; 70:622-628.
- Chua TP, Ponikowski P, Harrington D, Anker SD, Webb-Peploe K, Clark AL, Poole-Wilson PA, Coats AJS. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. *J Am Coll Cardiol* 1997; 29:1585-1590.
- Matsumoto A, Itoh H, Eto Y, Kobayashi T, Kato M, Omata M, Watanabe H, Kato K, Momomura S. End-tidal CO₂ pressure decreases during exercise in cardiac patients: association with severity of heart failure and cardiac output reserve. *J Am Coll Cardiol* 2000; 36:242-249.
- 11. Kano H, Koike A, Hoshimoto-Iwamoto M, Nagayama O, Sakurada K, Suzuki T, Tsuneoka H, Sawada H, Aizawa T, Wasserman K. Abnormal end-tidal PO₂ and PCO₂ at the anaerobic threshold correlate well with impaired exercise gas exchange in patients with left ventricular dysfunction. *Circ J* 2012; 76:79-87.
- Yajima T, Koike A, Sugimoto K, Miyahara Y, Marumo F, Hiroe M. Mechanism of periodic breathing in patients with cardiovascular disease. *Chest* 1994; 106:142-146.
- Ben-Dov I, Sietsema KE, Casaburi R, Wasserman K. Evidence that circulatory oscillations accompany ventilatory oscillations during exercise in patients with heart

failure. Am Rev Respir Dis 1992; 145:776-781.

- 14. Casaburi R, Whipp BJ, Wasserman K, Beaver WL, Koyal SN. Ventilatory and gas exchange dynamics in response to sinusoidal work. *J Appl Physiol* 1977; 42:300-311.
- 15. Shimizu N, Koike A, Koyama Y, Kobayashi K, Marumo F, Hiroe M. Kinetics of pulmonary gas exchange during and while recovering from exercise in patients after anterior myocardial infarction. *Jpn Circ J* 1999; 63:459-466.

FIGURE LEGENDS

- Figure 1. Panel A: Changes in the O₂ uptake (VO₂), CO₂ output (VCO₂), and gas exchange ratio (R) during cardiopulmonary exercise testing in a patient with the spiral phenomenon. Panel B: VCO₂-versus-VO₂ plot produced from the data of panel A. Panel C: Changes in VO₂, VCO₂, and R during cardiopulmonary exercise testing in a patient without the spiral phenomenon. Panel D: VCO₂-versus-VO₂ plot produced from the data of panel C.
- Figure 2. Brain natriuretic peptide (BNP) (panel A), left ventricular ejection fraction (LVEF)
 (panel B), peak O₂ uptake (VO₂) (panel C), and slope of the increase in ventilation
 versus the increase in CO₂ output (VE-VCO₂ slope) (panel D) plotted against the
 cycle length of VO₂ oscillations.
- Figure 3. Brain natriuretic peptide (BNP) (panel A), left ventricular ejection fraction (LVEF)
 (panel B), peak O₂ uptake (VO₂) (panel C), and slope of the increase in ventilation
 versus the increase in CO₂ output (VE-VCO₂ slope) (panel D) plotted against the
 phase difference between VO₂ and VCO₂ oscillations.

	All patients	A Spiral P		
Characteristics		YES	NO	p value
	(n = 126)	(n = 49)	(n = 77)	
Male/female	103 / 23	42 / 7	61 / 16	NS
Age (years)	63 ± 12	65 ± 11	61 ± 13	NS
Height (cm)	166 ± 8	165 ± 8	167 ± 9	NS
Weight (kg)	65 ± 13	65 ± 13	65 ± 12	NS
Body mass index (kg/m ²)	24 ± 4	24 ± 4	23 ± 4	NS
Etiology				
Valvular disease	35 (28%)	14 (29%)	21 (27%)	NS
Coronary artery disease	35 (28%)	12 (24%)	23 (30%)	NS
Idiopathic dilated cardiomyopathy	20 (16%)	12 (24%)	8 (10%)	0.035
Hypertrophic cardiomyopathy	10 (8%)	2 (4%)	8 (10%)	NS
Other cardiac disease	26 (21%)	9 (18%)	17 (22%)	NS
Medication				
-blockers	82 (65%)	40 (82%)	42 (55%)	0.002
ACEI/ARB	67 (53%)	26 (53%)	41 (53%)	NS
Diuretics	62 (49%)	32 (65%)	30 (39%)	0.004
Ca-channel blockers	33 (26%)	10 (20%)	23 (30%)	NS
Nitrates	20 (16%)	9 (18%)	11 (14%)	NS
Digitalis	7 (6%)	7 (14%)	0	0.001

Table 1. Patient characteristics in patients with and without a spiral phenomenon

Data are presented as the mean \pm SD.

ACEI, Angiotensin converting enzyme inhibitor; ARB, Angiotensin receptor blocker;

NS, not significant.

	All patients	A Spiral Phenomenon		
Characteristics	(n = 126)	YES (n = 49)	NO (n = 77)	p value
At rest				
Creatinine (mg/dL)	1.1 ± 0.8	1.3 ± 1.2	0.9 ± 0.3	0.039
Brain natriuretic peptide (pg/mL)	398 ± 558	637 ± 698	228 ± 351	0.002
Left ventricular ejection fraction (%)	52 ± 20	43 ± 21	57 ± 17	< 0.001
Left ventricular diastolic dimension (mm)	54 ± 12	59 ± 14	51 ± 9	0.001
Left ventricular systolic dimension (mm)	40 ± 15	47 ± 17	36 ± 12	< 0.001
Heart rate (beats/min)	75 ± 16	76 ± 16	75 ± 15	NS
Systolic blood pressure (mmHg)	115 ± 24	109 ± 26	119 ± 22	0.018
Diastolic blood pressure (mmHg)	73 ± 15	71 ± 16	75 ± 14	NS
End-tidal PCO ₂ (mmHg)	32 ± 4	31 ± 4	33 ± 4	0.007
At peak exercise				
Heart rate (beats/min)	125 ± 33	117 ± 29	130 ± 35	0.026
Systolic blood pressure (mmHg)	163 ± 38	149 ± 42	172 ± 33	0.001
Diastolic blood pressure (mmHg)	81 ± 20	80 ± 21	82 ± 19	NS
End-tidal PCO ₂ (mmHg)	35 ± 5	33 ± 5	36 ± 5	0.001
Gas exchange ratio	1.10 ± 0.10	1.09 ± 0.11	1.11 ± 0.09	NS
Peak VO ₂ (mL/min/kg)	16.7 ± 6.3	14.5 ± 5.6	18.1 ± 6.3	0.002
Peak VO ₂ (%)	67 ± 23	60 ± 23	72 ± 21	0.006
VE-VCO ₂ slope	36 ± 9	40 ± 10	34 ± 7	< 0.001
Amplitude of VE (L/min)	6.3 ± 2.2	7.5 ± 2.5	5.6 ± 1.7	< 0.001
Amplitude of VE (%)	38 ± 13	45 ± 15	34 ± 10	< 0.001
Cycle length of VE (sec)	57 ± 16	65 ± 19	51 ± 12	< 0.001
Amplitude of VO ₂ (mL/min)	186 ± 64	203 ± 70	176 ± 58	0.023
Amplitude of VO ₂ (%)	46 ± 16	52 ± 19	42 ± 13	0.002
Cycle length of VO ₂ (sec)	56 ± 16	65 ± 17	51 ± 11	< 0.001
Amplitude of VCO ₂ (mL/min)	168 ± 56	187 ± 57	155 ± 52	0.002
Amplitude of VCO ₂ (%)	46 ± 16	53 ± 18	41 ± 14	< 0.001
Cycle length of VCO ₂ (sec)	56 ± 17	65 ± 19	51 ± 11	< 0.001
Phase difference between VO ₂ and VCO ₂ (sec)	2.2 ± 2.7	4.4 ± 3.0	0.7 ± 0.8	< 0.001

Table 2. Patient characteristics in patients with and without a spiral phenomenon

The brain natriuretic peptide was obtained in 87 patients (36 patients with a spiral phenomenon and 51 patients without it). Data are presented as the mean \pm SD.




Figure 2




Figure 3

